Avalo Therapeutics, Inc.AVTXNASDAQ
Loading
Year-over-year SG&A expense growth
| Period | Value |
|---|---|
| Q4 2025 | 17.18% |
| Q3 2025 | 6.39% |
| Q2 2025 | -5.48% |
| Q1 2025 | 5.98% |
| Q4 2024 | 22.10% |
| Q3 2024 | -5.34% |
| Q2 2024 | 41.81% |
| Q1 2024 | 19.32% |
| Q4 2023 | 7.47% |
| Q3 2023 | 2.60% |
| Q2 2023 | -10.38% |
| Q1 2023 | -8.48% |
| Q4 2022 | -9.90% |
| Q3 2022 | 17.96% |
| Q2 2022 | -76.17% |
| Q1 2022 | 95.35% |
| Q4 2021 | 0.93% |
| Q3 2021 | -19.96% |
| Q2 2021 | 38.50% |
| Q1 2021 | 5.40% |
| Q4 2020 | 0.73% |
| Q3 2020 | -25.45% |
| Q2 2020 | 101.43% |
| Q1 2020 | 169.17% |
| Q4 2019 | -191.29% |
| Q3 2019 | -0.17% |
| Q2 2019 | -8.70% |
| Q1 2019 | 6.38% |
| Q4 2018 | 30.55% |
| Q3 2018 | -17.48% |
| Q2 2018 | 14.41% |
| Q1 2018 | 11.27% |
| Q4 2017 | 85.59% |
| Q3 2017 | 49.52% |
| Q2 2017 | 8.18% |
| Q1 2017 | 21.49% |
| Q4 2016 | -35.71% |
| Q3 2016 | 4.06% |
| Q2 2016 | -38.21% |
| Q1 2016 | 37.69% |